牛牛AI助理已提取核心訊息
Li Dean Y, Executive VP & President of Merck & Co's MRL division, completed a sale of 14,702 shares of the company's common stock on February 9, 2024. The shares were sold at an average price of $125.4988, resulting in a total transaction value of approximately $1.85 million. Following the sale, Li's direct holdings in Merck & Co. amounted to 46,242.37 shares. The transaction was executed as an open market or private sale, following an acquisition of the same number of shares through the exercise or conversion of derivative security at a price of $62.07 per share.
Li Dean Y, Executive VP & President of Merck & Co's MRL division, completed a sale of 14,702 shares of the company's common stock on February 9, 2024. The shares were sold at an average price of $125.4988, resulting in a total transaction value of approximately $1.85 million. Following the sale, Li's direct holdings in Merck & Co. amounted to 46,242.37 shares. The transaction was executed as an open market or private sale, following an acquisition of the same number of shares through the exercise or conversion of derivative security at a price of $62.07 per share.
默沙東公司MRL部門執行副總裁兼總裁李迪安於2024年2月9日完成了14,702股公司普通股的出售。這些股票的平均價格爲125.4988美元，總交易額約爲185萬美元。出售後，李在默沙東的直接持股量爲46,242.37股。該交易是通過行使或轉換衍生證券以每股62.07美元的價格收購相同數量的股票後，以公開市場或私募方式執行的。
默沙東公司MRL部門執行副總裁兼總裁李迪安於2024年2月9日完成了14,702股公司普通股的出售。這些股票的平均價格爲125.4988美元，總交易額約爲185萬美元。出售後，李在默沙東的直接持股量爲46,242.37股。該交易是通過行使或轉換衍生證券以每股62.07美元的價格收購相同數量的股票後，以公開市場或私募方式執行的。
有用
沒用